Assessing the state of antibacterial drug discovery through patent analysis

Aylin Sertkaya; J Daniel McGeeney; Casey Sullivan; Allison Kolbe; Trinidad Beleche; Stephen Murphy; Ayesha Berlind; Amber Jessup

doi:10.1016/j.ijantimicag.2023.107051

Assessing the state of antibacterial drug discovery through patent analysis

Int J Antimicrob Agents. 2024 Feb;63(2):107051. doi: 10.1016/j.ijantimicag.2023.107051. Epub 2023 Dec 8.

Authors

Aylin Sertkaya¹, J Daniel McGeeney², Casey Sullivan³, Allison Kolbe³, Trinidad Beleche³, Stephen Murphy³, Ayesha Berlind², Amber Jessup⁴

Affiliations

¹ Eastern Research Group, Inc., Concord, MA, 01742, USA. Electronic address: aylin.sertkaya@erg.com.
² Eastern Research Group, Inc., Concord, MA, 01742, USA.
³ U.S. Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation, Office of Science and Data Policy, Washington, DC, 20201, USA.
⁴ U.S. Department of Health and Human Services, Office of Inspector General, Washington, DC, 20201, USA.

PMID: 38072169
DOI: 10.1016/j.ijantimicag.2023.107051

Abstract

Patent filings suggest increasing intensity of antibacterial drug discovery in recent years, but the share of patents published by commercial companies has declined.

Keywords: Antibacterial drug R&D; Antibacterial drug compound patents.

MeSH terms

Anti-Bacterial Agents*
Drug Discovery*

Substances

Anti-Bacterial Agents